The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
文摘
Deficits in appendicular and axial bone microarchitecture and strength are consistently observed in long-term hypoinsulinemic diabetes Normalization of glycemic control, via SGLT2I + insulin co-therapy, prevents diabetic bone disease in a mouse model of T1D Glycemic status is predictive of bone phenotype SGLT2-Inhibitor therapy alone may impart secondary effects on bone turnover. Monitoring the effects of SGLT2Is on skeletal outcomes remains relevant